MBRX

Moleculin Biotech, Inc. is a Phase III clinical-stage pharmaceutical company advancing a pipeline of therapeutic candidates addressing tumors and viruses. The Company is conducting a pivotal Phase III trial evaluating Annamycin, a non-cardiotoxic anthracycline, in combination with Cytarabine for the treatment of subjects with relapsed/refractory acute myeloid leukemia (AML). It has three core technologies and six drug candidates, three of which have shown human activity in clinical trials. Its core technologies consist of Annamycin, WP1066 Portfolio, and WP1122 Portfolio. Annamycin is designed to avoid multidrug resistance mechanisms and cardiotoxicity. Its WP1066, is an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other transcription factors, and its portfolio includes WP1193, and WP1220. Its WP1122 contains compounds including WP1096, and WP1097, which is designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG).

Wall Street analysts forecast MBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MBRX is 6.67 USD with a low forecast of 4.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Moleculin Biotech Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

Moleculin Biotech Inc. EPS for the last quarter amounts to -17.02 USD, decreased -76.13 % YoY.

Moleculin Biotech Inc (MBRX) has 17 emplpoyees as of December 15 2025.

Today MBRX has the market capitalization of 10.28M USD.